pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information
The conference call may be accessed by dialing (888) 679-8037 from the
U.S. and
A replay of the call will be available approximately two hours following
the end of the call through
The conference call will be available via the Internet at www.psivida.com and will also be distributed through the Thomson StreetEvents Network. Individual investors can listen to the call via www.earnings.com and Institutional investors can access the call via www.streetevents.com. The call will be archived and accessible on the Web site for approximately 30 days.
Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.
About
pSivida is a world leader in the development of miniaturized,
injectable, drug delivery systems for the eye. pSivida’s lead
development product, Iluvien®, delivers fluocinolone
acetonide (FA) for the treatment of diabetic macular edema (DME).
Formerly known as Medidur™ FA for DME, Iluvien is in fully recruited
Phase III clinical trials. pSivida has licensed certain drug delivery
technology to
pSivida owns the rights to develop and commercialize a modified form of silicon known as BioSilicon™, which has potential therapeutic applications. The most advanced BioSilicon product candidate, BrachySil™, delivers a therapeutic P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors. pSivida has completed an initial safety clinical trial of BrachySil for the treatment of pancreatic cancer and is conducting a follow-on dose-ranging clinical trial.
pSivida’s intellectual property portfolio consists of 45 patent
families, over 100 granted patents, including patents accepted for
issuance, and over 200 patent applications. pSivida conducts its
operations from
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking and involve a number of risks and uncertainties. All
statements that address activities, events or developments that we
intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause
actual results to differ materially from the forward-looking statements:
failure of FA or the Iluvien device to act as a VEGF inhibitor or
neuroprotectant; inability to expand the treatment indications for
Iluvien; maintaining key collaboration agreements with Alimera and
Pfizer; modification of existing terms of key collaboration agreements
with Alimera and Pfizer; uncertainties regarding the achievement of
milestones and other contingent contractual payment events; failure to
prove safety and efficacy of Iluvien or BrachySil; inability to raise
capital; continued losses and lack of profitability; inability to derive
revenue from Retisert; termination of license agreements; inability to
pay any registration penalties; inability to develop or obtain
regulatory approval for new products; inability to protect intellectual
property or infringement of others’ intellectual property; inability to
obtain partners to develop and market products; competition; risks and
costs of international business operations; manufacturing problems;
insufficient third-party reimbursement for products; failure to retain
key personnel; product liability; failure to comply with laws; failure
to achieve and maintain effective internal control over financial
reporting; impairment of intangibles; volatility of stock price;
possible dilution through exercise of outstanding warrants and stock
options or future stock issuances; possible influence by Pfizer; and
other factors that may be described in our filings with the
Source:
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak,
President
312-943-1123
bjedynak@janispr.com
or
In
Australia:
pSivida Corp
Brian Leedman, Vice President,
Investor Relations
+61 8 9227 8327
brianl@psivida.com
